Jeffrey Berger, MD
Cardiovascular Disease · New York, NYNPI 1912172701
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,522 of the $53,090 with a category attached, or 93.3%. Janssen Scientific Affairs, LLC accounts for 61.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $20,390 and has fallen 82.6% since, to $3,542 in 2025. Among cardiovascular disease clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $1516.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Scientific Affairs, LLC$32K
- Amarin Pharma, Inc.$6K
- Johnson & Johnson$6K
- Amgen$5K
- Bayer Healthcare LLC$4K
- E.r. Squibb & Sons, L.L.C.$825
- plus $53 from 2 others
Across 2 payments — averaging $67,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$135K
What the payments were for
- Consulting fees$49,52293%
- Travel & lodging$2,8145%
- Food & beverage$7541%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Scientific Affairs, LLC | 5 | $32,400 |
| Amarin Pharma, Inc. | 7 | $5,896 |
| Johnson & Johnson | 6 | $5,699 |
| Amgen | 11 | $4,712 |
| Bayer Healthcare LLC | 2 | $3,505 |
| E.r. Squibb & Sons, L.L.C. | 1 | $825 |
| Boehringer Ingelheim | 2 | $38 |
| Novo Nordisk | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,090 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $15,959 |
| Ezetimibe | 36 | $906 |
| Atorvastatin Calcium | 52 | $669 |
| Rosuvastatin Calcium | 49 | $551 |
| Metoprolol Succinate | 16 | $378 |
| Chlorthalidone | 13 | $191 |
| Amlodipine Besylate | 28 | $185 |
| Ramipril | 12 | $129 |
| Lisinopril | 17 | $104 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in New York
- Roger HajjarNew York$5.2M
- Gregg StoneNew York$2M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Megha PrasadNew York$813K
- Eyal HerzogNew York$645K
- Nisha JhalaniNew York$443K
- Roxana MehranNew York$432K
- Howard WeintraubNew York$328K
- Anuradha Lala-TrindadeNew York$324K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.